China Pharmaceutical Contract Manufacturing Services | Industry Analysis | Market Size | 2030

Owing to reasons, such as a booming economy and availability of skilled labor, outsourcing to Asian CMOs, primarily in China, is considered an attractive business model to pharmaceutical developers / sponsors, across the world.

Roots Analysis is pleased to announce the publication of its recent study, titled, “China Pharmaceutical Contract Manufacturing Services Market, 2020-2030.”

The report features an extensive study of the current market landscape and future opportunities associated with the pharmaceutical contract manufacturing market in China. The study also features a detailed analysis, highlighting the capabilities of pharmaceutical CMOs in this region. Amongst other elements, the report features:

  • A detailed assessment of the current market landscape of pharmaceutical contract manufacturers in China engaged in the development of active pharmaceutical ingredients (APIs), intermediates and finished dosage formulations (FDFs).
  • A detailed landscape of the pharmaceutical manufacturing facilities in China, including an analysis based on location of these facilities, highlighting key manufacturing hubs.
  • A brief discussion of various regulatory guidelines in China and various challenges, related to regulatory scrutiny, faced by pharmaceutical manufacturers in China.
  • Detailed profiles of key players that offer a diverse range of capabilities for the manufacturing of pharmaceutical products in China.
  • A review of the pharmaceutical manufacturing related initiatives of the top 10 big pharma players (shortlisted from the top companies of 2019 by revenues).
  • An analysis of the partnerships and acquisitions that have been established in this domain, in the recent past.
  • A detailed capacity analysis based on the installed reactor capacities of the manufacturing facilities in China.
  • A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.

A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

Request for Customization: 

Key Geographical Regions

  • Eastern China
  • Southern China
  • Northern China

Type of Product 

  • Active Pharmaceutical Ingredients (APIs)
  • Drug Products

Type of Drug Product

  • Solid
  • Liquid / Semi-Solid
  • Injectable
  • Others

Scale of Operation

  • Clinical
  • Commercial

Company Size

  • Small
  • Mid-Sized
  • Large / Very Large

Key players covered in the report

  • 2Y-Chem
  • Aurisco Pharmaceutical
  • ChemPartner
  • Dorrapharma
  • Hubei Biocause Pharmaceutical
  • Infoark
  • Ningbo Menovo Pharmaceutical
  • Shandong Xinhua Pharmaceutical
  • Shanghai Acebright Pharmaceuticals
  • STA Pharmaceutical
  • Zhejiang Huahai Pharmaceutical

Request for Sample:

Please Visit Our Upcoming Reports

Gonorrhea: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031

Non-Viral Drug Delivery Systems (Focus on Intracellular Technologies and Intracellular Biologics) Market

Lactose Intolerance: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031

Helicobacter pylori (H. pylori) Infection: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031

Cold Chain Logistics Market, Industry Trends and Global Forecasts, 2021-2030

This post was created with our nice and easy submission form. Create your post!

What do you think?

Posted by Stella Wilson

Leave a Reply

Your email address will not be published. Required fields are marked *

GIPHY App Key not set. Please check settings

Explained: The Furucombo Evil Contract Hack (Feb 2021)

Polkadot price analysis: DOT recovers above $35

Polkadot price analysis: DOT recovers above $35